BioLife SolutionsBLFS +4.25%72 PB Ratio is 3.76 as of Jun. 27, 2026, which is 1% above its 10-year median of 3.71. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.57 (Fairly Valued). The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 70.56% on this metric.
BioLife Solutions Inc stock PB Ratio (=3.76) is close to 3-year high of 3.9.
The historical rank and industry rank for BioLife Solutions's PB Ratio or its related term are showing as below:
BLFS'
s PB Ratio Range Over the Past 10 Years
Min: 1.08 Med: 3.71 Max: 24.75
Current: 3.76
During the past 13 years, BioLife Solutions's highest PB Ratio was 24.75. The lowest was 1.08. And the median was 3.71.
BLFS's PB Ratio is ranked worse than 70.56% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs BLFS: 3.76
During the past 12 months, BioLife Solutions's average Book Value Per Share Growth Rate was 2.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -3.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -1.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 42.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioLife Solutions was 394.20% per year. The lowest was -71.10% per year. And the median was -10.45% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioLife Solutions PB Ratio Related Terms
BioLife Solutions PB Ratio Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, BioLife Solutions's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioLife Solutions (BLFS) has a PB Ratio of 3.76 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioLife Solutions and its competitors. This is near median its historical median of 3.71. Over the past decade, BioLife Solutions' PB Ratio has ranged from 1.08 to 24.75. According to the industry distribution chart, BioLife Solutions ranks #556 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 70.6%.
Is BioLife Solutions' PB Ratio too high?
BioLife Solutions' current PB Ratio of 3.76 is near median its 10-year median of 3.71. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 24.75. The Medical Devices & Instruments industry median PB Ratio is 2.02. BioLife Solutions' value of 3.76 is 86.1% above this industry median. Based on the distribution chart, BioLife Solutions ranks #556 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' PB Ratio compare to KMTS and AZTA?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #556 out of 788 companies for PB Ratio. This places BioLife Solutions in the lower half of its industry. The industry median PB Ratio is 2.02. BioLife Solutions' value of 3.76 is 86.1% above this benchmark. Historically, BioLife Solutions' own PB Ratio has ranged from 1.08 to 24.75 over the past decade. While the company's 10-year median is 3.71 vs. the industry median of 2.02, BioLife Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current PB Ratio of 3.76 is 86.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current PB Ratio is 3.76, which is near median its own 10-year median of 3.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.57, compared to a current price of $28.64 — trading 0.2% above its estimated fair value. The current PB Ratio is 3.76, which is near median its 10-year median of 3.71 and 86.1% above the Medical Devices & Instruments industry median of 2.02. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current PB Ratio is 3.76 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
PB Ratio: 3.76 (near median its 10-year median of 3.71)
GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
Industry Position: 86.1% above the Medical Devices & Instruments median (#556 of 788)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
